Today’s Patent – Integrated Insulin Delivery System with Continuous Glucose Sensor

The said invention (US12246166B2) was invented by John Michael Dobbles, Apurv Ullas Kamath, Aarthi Mahalingam, James H. Brauker, and patented by USPTO on July 26^th, 2024. Currently, it stands assigned to the Dexcom Inc.

This invention relates to an integrated system and method for determining insulin therapy using real-time data from a continuous glucose sensor, a receiver device, and an insulin delivery mechanism. The system allows a user or healthcare provider to set customizable glucose targets, which may vary by time of day. The receiver device processes live glucose readings, predicts future glucose levels using algorithmic modelling, and calculates insulin therapy instructions based on user-defined glucose targets and internal data such as insulin sensitivity, insulin-on-board, and metabolic responses. These instructions are transmitted to an insulin delivery device to maintain the user’s glucose within a desired range or achieve a euglycemic state.

The system supports dynamic glucose target adjustments based on scheduled time windows, real-time user activity, or changes in physiological response. By analyzing both historical and predicted glucose levels in conjunction with programmed glucose targets, the system provides adaptive, patient-specific insulin dosing recommendations. This can improve glycemic control and reduce the risk of hypo- or hyperglycemia. The receiver may also display current glucose data, future predictions, and insulin dosing recommendations, and may be integrated with or separate from the insulin delivery device, which could include an infusion pump.